Picture supply: Getty Pictures
With rates of interest falling from latest highs, I believe dividend shares are again in trend in 2026. Two of the largest names alone watchlist are Lloyds (LSE: LLOY) and GSK (LSE: GSK).
Each are giant, regular dividend payers which have loved robust latest share worth runs, which makes them price a better search for earnings buyers.
Lloyds shares flying excessive
Lloyds has had a robust yr with its shares sitting round 100p as I write late on 9 January following a 85.5% acquire within the final 12 months.
Greater rates of interest have helped the corporate earn extra from loans, and the financial institution has been blissful to share a few of that with buyers.
Regardless of the robust yr, there are nonetheless clear dangers. Lloyds could be very centered on the UK in comparison with world banking friends like HSBC. A weaker housing market or a bounce in dangerous money owed may hit earnings and put strain on future dividends. Falling rates of interest may additionally put strain on its internet curiosity margin as competitors for loans heats up.
Whereas a few of the uncertainty round its motor finance scandal has cleared, regulatory dangers stay an ever-present menace within the sector, which may have actual impacts on future payouts.
Rebounding GSK nears 52-week excessive
GSK has additionally had a robust run. The corporate’s shares are altering arms for 1,882p which isn’t removed from a 52-week excessive. The final month acquire of 39.4% has been underpinned by extra confidence round its medicines pipeline and decreased commerce tariff fears.
New therapies, together with promising work in areas equivalent to hepatitis B and vaccines, are serving to to construct a stable pipeline. That’s essential for the corporate’s earnings base and future dividends.
That mentioned, drug improvement is rarely easy. Trials can fail, regulators can say no, and the corporate faces patent expiries on some present merchandise later within the decade.
If new medicines don’t progress as deliberate, earnings and dividend progress may each gradual and affect on payouts to buyers.
Valuation
To me, Lloyds appears pretty priced fairly than low-cost. The corporate’s price-to-book (P/B) ratio of 1.3 is consistent with HSBC (1.4) and NatWest (1.2), however increased than Barclays (0.9). Equally, on a dividend yield foundation, its 3.3% determine is comparable or barely beneath friends.
GSK is presently yielding round 3.4% with a price-to-earnings (P/E) ratio of 14.1. That compares favourably to AstraZeneca with a P/E ratio nudging 32, however stays consistent with the broader Footsie common.
My verdict
Each Lloyds and GSK appear to be basic dividend shares for buyers to look at carefully in 2026. They mix common earnings with robust latest share worth features and clear methods, albeit in very completely different industries.
Nonetheless, nothing is assured. Lloyds stays tied to the well being of the UK financial system by way of the efficiency of its mortgage e-book, whereas GSK should hold progressing its analysis and improvement efforts.
Primarily based on basic funding metrics, I don’t assume both of those shares is undervalued. Nonetheless, they’re stable dividend shares which are price contemplating for buyers looking for so as to add extra high quality and yield to their portfolios in 2026.
